The Scripps Research Institute has licensed to Poniard Pharmaceuticals a class of protein kinase inhibitors for treating a variety of diseases, capping a research collaboration begun in 2005, Poniard and Scripps said this week.
The agreement, which gives the drug maker access to a class of compounds that have shown anti-cancer activity, also marks the first time that Scripps Research Institute’s Florida facility has outlicensed a technology developed through an industry-sponsored research agreement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.